Table 1.
Patients' baseline characteristics.
| Categorya | Statistics - Total patients 164 |
|---|---|
| Age—yr (range) | 75 (60-86) |
| Subgroup—no. (%) | |
| <65 yr | 1 (.6) |
| ≥75 yr | 83 (50.6) |
| Gender | |
| Male—no. (%) | 79 (48.17) |
| Female—no. (%) | 85 (51.83) |
| Frailty score—no. (%) | |
| Fit | 19 (11.6) |
| Unfit | 22 (13.4) |
| Frail | 17 (10.36) |
| NE | 106 (64.64) |
| Type of myeloma—no. (%) | |
| IgG κ | 70 (42.68) |
| IgG λ | 28 (17.1) |
| IgA κ | 25 (15.23) |
| IgA λ | 15 (9.15) |
| IgD κ | 2 (1.22) |
| IgD λ | 1 (.6) |
| IgM | 0 (0) |
| Light chain κ | 14 (8.54) |
| Light chain λ | 6 (3.66) |
| Non-secretory | 3 (1.82) |
| ISS stage—no. (%) | |
| I | 61 (37.2) |
| II | 35 (21.34) |
| III | 35 (21.34) |
| NE | 33 (20.12) |
| Cytogenetics—no. (%) | |
| Normal | 32 (19.51) |
| Altered, w/o high risk cytogenetics | 31 (18.9) |
| Altered, w/high risk cytogenetics | 10 (6.1) |
| NE | 91 (55.49) |
| MGUS | |
| Y | 70 (42.68) |
| N | 92 (56.10) |
| NE | 2 (1.22) |
| PET—no. (%) | |
| + | 55 (33.55) |
| (+, LRT treated subgroup) | 10 |
| – | 16 (9.75) |
| NE | 93 (56.7) |
a
ISS, international staging system; MGUS, monoclonal gammopathy of undetermined significance; PET, positron emission tomography; LRT, local radiotherapy; NE, not evaluated.